CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03805841
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:05.839385+00:00
Published At: 2023-06-28T00:00:00+00:00
Record Updated At: 2023-06-28
Results Posted At: 2023-06-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["NSCLC, Stage IV", "NSCLC Stage IIIB", "NSCLC, Stage IIIC", "NSCLC, Recurrent", "EGFR Exon 20 Insertion Mutation", "HER2-activating Mutation", "ERBB Fusion", "NRG1 Fusion"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-06-28"
protocolSection.identificationModule.nctId: "NCT03805841"
protocolSection.identificationModule.officialTitle: "Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-06-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.